Actively Recruiting

Phase Not Applicable
Age: 6Years - 18Years
All Genders
NCT04540432

Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment

Led by Centre Hospitalier Universitaire de Nīmes · Updated on 2025-11-17

25

Participants Needed

4

Research Sites

405 weeks

Total Duration

On this page

Sponsors

C

Centre Hospitalier Universitaire de Nīmes

Lead Sponsor

U

University Hospital, Montpellier

Collaborating Sponsor

AI-Summary

What this Trial Is About

Idiopathic juvenile arthritis includes 20% of patients with arthritis with enthesitis or juvenile spondyloarthropathy. This is treated with anti-inflammatory drugs and then followed by biotherapy with DMARDs (Drugs Modifying the Activity of Rheumatic Disease) if the former are insufficient. Methotrexate (MTX) may also be used before these biotherapies. Recently, in adults, a particular profile of intestinal microbiota has been shown to alter the availability of MTX making it in efficient. Knowing that pediatric patients with juvenile spondyloarthropathy have an imbalance of their intestinal flora (dysbiosis) the investigators wanted to explore whether DMARDs could have a similar impact on the microbiota of these young patients and alter the response to treatment.

CONDITIONS

Official Title

Evolution of Intestinal Microbiota in Patients With Juvenile Spondylarthropathy According to Typology of Treatment

Who Can Participate

Age: 6Years - 18Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Patients aged over 6 and under 17 years old (included)
  • Diagnosed with arthritis with juvenile enthesitis according to ILAR criteria
  • Not treated with methotrexate or biotherapy for at least 3 months
  • Not treated with cortisone for over 1 month
  • Parents have given written informed consent
  • Consent form signed by legal guardian
  • Covered by Social Security or private health insurance
Not Eligible

You will not qualify if you...

  • Enrolled in another category 1 study or participated in one within 3 months prior to inclusion
  • Within an exclusion period determined by another study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 4 locations

1

Nîmes University Hospital

Nîmes, Gard, France, 30029

Actively Recruiting

2

Montpellier University Hospital, Arnaud de Villeneuve Hospital

Montpellier, Hérault, France, 34295

Actively Recruiting

3

APHM, Hopital Nord

Marseille, France

Actively Recruiting

4

Hopital des enfants, CHU de Toulouse

Toulouse, France

Not Yet Recruiting

Loading map...

Research Team

T

Tu-Anh TRAN, Professor

CONTACT

J

Jean-Philippe LAVIGNE, Professor

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

6

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here